ImmuneSensor Therapeutics
PrivateLast Round
Series A
Dec 5, 2022
Est. Valuation
$110M
Total Funding Raised
$26.1M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
ImmuneSensor Therapeutics operates in Healthcare & Life Sciences and is based in Dallas, Texas. Its latest recorded funding round was a Series A round in December 2022.
ImmuneSensor Therapeutics is a biotechnology company that develops novel medicines targeting the cGAS-STING pathway to treat cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmuneSensor Therapeutics Comparables
Compare ImmuneSensor Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| IFM Therapeutics | 86% | |
| Roivant Sciences | 78% | |
| STINGINN, LLC | 77% |
For institutional investors. Book with your work email.
ImmuneSensor Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 5, 2022 | ||||
| Grant | Sep 20, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ImmuneSensor Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cancer Prevention and Research Institute of Texas | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 54% MoM, reaching 2.9K.
- Sep 20, 2022
$16.1M grant from Cancer Prevention and Research Institute of Texas.
For institutional investors. Book with your work email.
ImmuneSensor Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ImmuneSensor Therapeutics's valuation, stock price, and market status.
Is ImmuneSensor Therapeutics a public or private company?
ImmuneSensor Therapeutics is a private company.
What is the current stock price of ImmuneSensor Therapeutics?
ImmuneSensor Therapeutics is a private company, so its shares have no public market price. Caplight tracks ImmuneSensor Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ImmuneSensor Therapeutics worth (valuation)?
ImmuneSensor Therapeutics's valuation is estimated at $110.0M based on funding round data.
Can I buy ImmuneSensor Therapeutics stock?
ImmuneSensor Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ImmuneSensor Therapeutics's last funding round?
ImmuneSensor Therapeutics's most recent funding round was Series A on December 5, 2022.
Who are the main investors in ImmuneSensor Therapeutics?
Key investors in ImmuneSensor Therapeutics include Cancer Prevention and Research Institute of Texas.
Will ImmuneSensor Therapeutics IPO soon?
No public IPO plans have been announced for ImmuneSensor Therapeutics.
How can I track ImmuneSensor Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in ImmuneSensor Therapeutics's shares on secondary markets.